Sugi Predict

Sugi Predict / Compounds / SCHEMBL8840142

SCHEMBL8840142

SCHEMBL8840142

CC(C)(C)c1nnc(C(=O)O)o1

nearest known ligand 0.49

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 1/20 0.39
▸ DPP4 P27487 3/20 0.37
▸ DPP8 Q6V1X1 3/20 0.37
▸ DPP7 Q9UHL4 2/20 0.37
▸ ELANE P08246 9/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ RAF1 P04049 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ GRN P28799 1/20 0.32
▸ SORT1 Q99523 1/20 0.32
▸ PDK2 Q15119 1/20 0.31
▸ BTK Q06187 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29069466 0.98 PTPN1 (0.38) PTPN1DPP4DPP8DPP7ELANE
SCHEMBL2678471 0.81 DPP4 (0.36) DPP4DPP8DPP7ELANERAF1
Potassium Ion SCHEMBL20532960 0.79 DPP4 (0.36) DPP4DPP8DPP7ELANERAF1
SCHEMBL17645774 0.79 DPP4 (0.39) DPP4DPP8DPP7ELANERAF1
SCHEMBL3976687 0.78 PTPN1 (0.39) PTPN1DPP4DPP8ELANE
SCHEMBL21366084 0.78 DPP4 (0.38) DPP4DPP8DPP7ELANERAF1
SCHEMBL17664593 0.76 DPP4 (0.40) DPP4DPP8DPP7ELANERAF1
SCHEMBL17040253 0.75 PTPN1 (0.50) PTPN1
SCHEMBL21067660 0.75 ELANE (0.38) DPP4DPP8DPP7ELANE
SCHEMBL21067661 0.75 ELANE (0.38) DPP4DPP8DPP7ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220389004-A1 FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) EMD Serono Research and Development Institute, Inc. 2022-12-08 — — US claimed
EP-3843847-A1 FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Merck Patent GmbH (DE) 2021-07-07 — — EP claimed
CN-112930213-A Fused imidazopyridines as reversible inhibitors of Bruton's Tyrosine Kinase (BTK) 默克专利有限公司 2021-06-08 — — CN claimed
WO-2020043638-A1 FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) MERCK PATENT GMBH (DE) 2020-03-05 — — WO claimed
US-12415803-B2 Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) MERCK PATENT GMBH (DE) 2025-09-16 — — US disclosed
US-20250034150-A1 BTK INHIBITORS BIOGEN MA INC. 2025-01-30 — — US disclosed
CN-117567453-A Benzazepine analogs as inhibitors of bruton's tyrosine kinase 渤健马萨诸塞州股份有限公司 2024-02-20 — — CN disclosed
EP-3609886-B1 BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE BIOGEN MA INC (US) 2024-02-07 — — EP disclosed
US-11858926-B2 Inhibiting agents for bruton's tyrosine kinase BIOGEN MA INC. (US) 2024-01-02 — — US disclosed
EP-4249071-A2 BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE Biogen MA Inc. (US) 2023-09-27 — — EP disclosed
CN-110621670-B Benzazepine analogs as inhibitors of bruton's tyrosine kinase 比奥根MA公司 2023-09-15 — — CN disclosed
WO-2023086521-A1 BTK INHIBITORS BIOGEN MA INC. (US) 2023-05-19 — — WO disclosed
WO-2018035080-A1 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2018-02-22 — — WO disclosed
US-20180051024-A1 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2018-02-22 — — US disclosed
EP-3204382-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2017-08-16 — — EP disclosed
WO-2016057500-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2016-04-14 — — WO disclosed
US-20160096834-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2016-04-07 — — US disclosed
US-20120202856-A1 SUBSTITUTED BENZIMDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2012-08-09 — — US disclosed
US-5591695-A Herbicidal [1,3,4]oxadiazoles and thiadiazoles AMERICAN CYANAMID CO. (US) 1997-01-07 — — US disclosed
EP-0726263-A2 Herbicidal (1,3,4)oxadiazoles and thiadiazoles American Cyanamid Company (US) 1996-08-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202856-A1 SUBSTITUTED BENZIMDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS TRPM8, TRPV1, TRPA1 PTPN1 2752/4885DPP4 508/4885DPP8 96/4885
US-20160096834-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF BTK, SYK, LYN PTPN1 86/4885DPP4 2792/4885DPP8 2471/4885
US-20180051024-A1 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF BTK, SYK, LCK PTPN1 80/4885DPP4 1932/4885DPP8 2188/4885
US-12415803-B2 Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) BTK, SYK, ABL1 PTPN1 93/4885DPP4 2004/4885DPP8 2395/4885
US-20250034150-A1 BTK INHIBITORS BTK, SYK, LYN PTPN1 34/4885DPP4 3123/4885DPP8 3487/4885
US-11858926-B2 Inhibiting agents for bruton's tyrosine kinase ABL1, BTK, LYN PTPN1 149/4885DPP4 3827/4885DPP8 3513/4885
US-20220389004-A1 FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) BTK, SYK, ABL1 PTPN1 93/4885DPP4 2004/4885DPP8 2395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.